ArticleAnnals of medicine and surgery (2012)2025
Monkey pox resurgence in South Asia: Pakistan's 2024 case highlights global health challenges.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The World Health Organization (WHO) has issued a serious worldwide notice regarding Monkey pox (Mpox), designating it as a public health emergency. Mpox, which began from West and Central Africa, has since migrated to non-endemic areas, such as South Asia. In 2024, Pakistan reported the first incidence of the disease, which was connected to a visitor from Saudi Arabia. The virus, which was previously primarily harming youth in Africa, is increasingly impacting a wider demographic, especially adults and men who have sex with other men (MSM) which usually are occurring in sexual health clinics. Engaging in sexual intercourse, inhaling droplets, and coming into contact are the three ways that the disease escalates. The risk is highest in underprivileged communities that are often stigmatized and have little access to primary healthcare. Antivirals such as brincidofovir, cidofovir, and tecovirimat are now used in treatment; in an emergency, vaccinations like JYNNEOS and Vaccinia Immune Globulin Intravenous (VIGIV) are also available. In regions where vaccine supplies are scarce, targeted and ring vaccination programs are essential. To cease the transmission of Mpox and lessen its effects on public health, increased surveillance, travel restrictions, and focused preventative efforts are crucial to aid non endemic countries from these catastrophes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.